CD8A and metabolic dysfunction-associated steatohepatitis: A recent study published in Nature involving 1,656 patients with advanced HCC showed that NASH-HCC patients did not benefit from ICIs treatment, possibly due to impaired immune surveillance of CD8+ T cells in NASH patients, resulting in poor response to ICIs and even induce MASH-HCC (Pfister et al., 2021).